Status:
UNKNOWN
Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
Lead Sponsor:
Fudan University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
Epithelial ovarian cancer is mostly diagnosed at late stage (III/IV), and the standard treatment for ovarian cancer includes primary debulking surgery and platinum-based adjuvant chemotherapy. However...
Detailed Description
Epithelial ovarian cancer (EOC) is one of the most common malignant tumors in women. Due to the insidious onset and the lack of effective early diagnosis measures, about 70% of patients with epithelia...
Eligibility Criteria
Inclusion
- Female patients over 18 years of age.
- ECOG 0-2
- Clinically confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer
- FIGO2014 stage III/IV
- Sign the informed consent form
- Good compliance and agree to cooperate with survival follow-up
Exclusion
- Patients with large abdominal masses or other reasons for not being able to tolerate surgical treatment
- Patients with severe medical comorbidities that cannot be corrected in the short term and are not suitable for tumor cytoreductive surgery
- Patients with contraindications to chemotherapy
- Patients with a history of psychotropic substance abuse and unable to quit or patients with mental disorders
- Patients with serious safety hazards or concomitant diseases that, in the judgment of the institution, would affect the patient's ability to complete the study
Key Trial Info
Start Date :
July 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05371301
Start Date
July 16 2021
End Date
December 1 2023
Last Update
May 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Shanghai, Shanghai Municipality, China, 200000